NEW YORK (Reuters Health) – Tight glycemic control may increase the risks of mortality and cardiovascular disease, new research suggests. Moderate control, with glycosylated hemoglobin A1c (HbA1c) levels…
NEW YORK (Reuters Health) – Only two visits to the pulmonary function lab — one for pre- and post-bronchodilatory spirometry and one for a methacholine challenge test —…
NEW YORK (Reuters Health) – Treating septic shock with steroids produces hyperglycemia, but patients are no better off with intensive insulin therapy than with conventional glucose control, according…
NEW YORK (Reuters Health) – It makes no difference whether internal tocodynamometry or external monitoring is used during induced or augmented labor – either way, the rate of…
NEW YORK (Reuters Health) – High-dose atorvastatin does not protect against contrast-induced nephropathy (CIN) in patients with kidney disease, Italian researchers report. “Statins have recently been proposed for…
NEW YORK (Reuters Health) – Endovascular treatment of intracranial aneurysms 3 mm or smaller in diameter is difficult and risky — but it’s successful in over 90% of…
NEW YORK (Reuters Health) – Cladribine and fingolimod, the first oral agents for multiple sclerosis (MS), significantly reduce relapse rates, risks of disability progression, and disease activity, according…
NEW YORK (Reuters Health) – A substantial proportion of women with cervical cancer who receive curative-intent radiotherapy will soon develop pelvic fractures, clinicians from the University of Texas…
NEW YORK (Reuters Health) – The nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and didanosine, and the protease inhibitors (PIs) indinavir and lopinavir-ritonavir, all increase the risk of myocardial…
NEW YORK (Reuters Health) – Daily treatment with diazoxide prompts a decrease in HbA1c in patients with newly diagnosed type 1 diabetes, Norwegian researchers report in the December…
